Introduction: A Market That Outgrew Its Own Definition
The telemedicine market
is the combined system of technologies, clinical services, payment rules and
public programmes through which care is delivered when patient and clinician
are in different places. Video consultation is its most recognisable face, but
the market now also spans audio-only visits, asynchronous messaging, remote
physiologic monitoring, virtual specialty and behavioural health programmes,
direct-to-consumer prescribing platforms, hospital-at-home models, and
government-run networks that connect rural clinics to distant specialists. Its
significance is practical rather than futuristic. Telemedicine is one of the
few tools health systems have for stretching scarce clinician capacity across
geography, and in many countries it has become a standing part of how people
reach care.
Explore the Telemedicine Market
Discover key trends, technologies, applications, and
growth opportunities shaping the global Telemedicine Market. Gain insights into
virtual consultations, remote healthcare delivery, digital platforms, and
evolving patient care models. Understand market dynamics, competitive
developments, regional opportunities, and emerging innovations driving
telemedicine adoption. Read the Full Report: https://www.igtps.com/report/telemedicine-market
The pandemic compressed a decade of adoption into a few
months. Among U.S. office-based physicians, the share whose practices used
telemedicine rose from 15.4 percent in 2019 to 86.5 percent in 2021. Consumer
use then settled rather than collapsed, 37.0 percent of U.S. adults reported a
telemedicine appointment in the prior twelve months in 2021, falling to 30.1
percent in 2022. The international picture is similar but far from uniform.
Across 22 OECD countries with comparable data, teleconsultations made up 13
percent of all doctor consultations in 2023, exceeding 25 percent in Denmark,
Estonia, Israel, Portugal and Sweden while remaining very low in Chile,
Germany, Greece and Korea. The spread between those countries reflects policy
and payment choices far more than it reflects technology.
That stabilisation is why adopting the latest
technologies and business models matters now. When a base of demand is
established, offering a video visit is no longer a differentiator. Advantage
moves to what is built around the visit, software that removes clinician
workload, payment models that reward outcomes rather than volume, monitoring
that extends care between encounters, and integration with local providers.
This article examines five developments that are reshaping the market in 2026,
followed by an analysis of recent company activity and the risks that could
change the trajectory. It draws only on government, international organisation,
research-institution and official company sources, and it deliberately avoids
commercial market-size estimates, which are difficult to verify and often
inconsistent in definition.
The Market Reality Check: Growth Is Real but Unevenly
Distributed
The most recent quarterly filings give the clearest read
on where value is moving. Teladoc Health reported second-quarter 2026 revenue
of 606.9 million dollars, down 4 percent year over year, on 4.1 million visits,
with U.S. integrated care members at 100.3 million compared with 102.4 million
a year earlier. Amwell reported revenue of 52.0 million dollars against 70.9
million in the same quarter of 2025, a decline of roughly 27 percent. Hims
& Hers Health, by contrast, reported revenue of 753.2 million dollars, up
38 percent, with subscribers approaching 2.9 million.
These results say that the market is not shrinking but is
reallocating. Money is leaving the model in which a vendor is paid per access
fee or per on-demand visit, and flowing toward three other models, recurring
condition-specific programmes, insurer-reimbursed care, and consumer platforms
that sell an ongoing treatment plan rather than a consultation. Amwell itself
lists weak growth and increased volatility in the telehealth market among the
risks it discloses to investors. That is a company statement and should be read
as such, but it is consistent with the pattern in the numbers.
Policy as Market Architecture
In telemedicine, regulation does not merely constrain the
market; it defines its edges. The clearest evidence comes from what happens
when policy lapses. HHS reports a 24 percent drop-in fee-for-service
telemedicine visits following the lapse of Medicare telehealth flexibilities in
September 2025. Demand for virtual care is real, but a meaningful share of it
depends on payment rules that Congress has repeatedly treated as temporary.
Medicare: a longer runway that is still not permanent
Following the 2025 lapse, the Consolidated Appropriations
Act, 2026 restored and extended the main Medicare flexibilities through 31
December 2027. HHS and CMS describe the extension as covering home as an
originating site, the absence of geographic restrictions for non-behavioural
services, the expanded list of eligible practitioners, audio-only delivery for
non-behavioural services, and the ability of rural health clinics and federally
qualified health centres to act as distant sites. Behavioural health telehealth
is on firmer footing, but even there the in-person visit requirement is waived
only through the end of 2027. The same law also directs CMS to introduce
billing modifiers to flag certain telehealth arrangements, including services
furnished incident to another service, which will make telehealth utilisation
more visible to payers and auditors. For operators, the practical consequence
is a planning horizon of roughly fifteen months on the fee-for-service side,
with a renewed cliff at the end of 2027.
Controlled substances: the nearer cliff
The sharper deadline sits in prescribing. DEA and HHS
issued a fourth temporary extension of the telemedicine flexibilities for
controlled medications, running through 31 December 2026. HHS notes that more
than 7 million controlled-medication prescriptions were issued via telemedicine
in 2024 without a prior in-person visit. Permanent rules have been pending
since the January 2025 proposal for a Special Registration for Telemedicine,
and a trade association for state controlled-substance authorities reports that
DEA sent a final special registration rule to the Office of Management and
Budget for review on August 2026. The text has not been published, so its
content is unknown. What can be said is that the outcome will matter
disproportionately to behavioural health, addiction treatment and
direct-to-consumer prescribing platforms, whose economics depend on being able
to start care without an in-person visit.
What the 2026 Physician Fee Schedule made durable
Not everything is temporary. In the final CY 2026
Physician Fee Schedule, CMS streamlined the process for adding services to the
Medicare telehealth list by dropping the distinction between provisional and
permanent services and asking mainly whether a service can be delivered by
two-way audio-video. It permanently removed frequency limits for subsequent
inpatient visits, nursing facility visits and critical care consultations
delivered by telehealth, and permanently adopted a definition of direct supervision
that allows supervision through real-time audio-video. It also extended payment
for FDA-authorised digital mental health treatment devices to cover a digital
therapy device for ADHD. These are quieter changes than the headline
extensions, but they are the ones that convert telehealth from an emergency
exception into ordinary clinical infrastructure.
From Visits to Outcomes: Payment Redesign and Remote
Monitoring
Medicare experiments with paying for results
The most consequential structural development of 2026 may
be the CMS Innovation Center's ACCESS model. It is a ten-year national test,
running from July 2026 through June 2036, that pays for outcomes rather than
individual services and gives care teams flexibility to choose the technology
and clinical tools that suit each patient. CMS says the model is designed to
support technology-supported care for people with chronic conditions, including
chronic musculoskeletal pain, and specifies that there is no cost-sharing for
the separate co-management payment that primary care or referring clinicians
can bill when they coordinate with ACCESS participants. This matters for telemedicine
because Medicare fee-for-service has historically paid for a visit, not for the
continuous digital coaching, monitoring and asynchronous contact that make
virtual chronic care work. ACCESS creates a payment pathway for that activity,
and it invites virtual-first companies to compete on results.
Remote monitoring gets cheaper to bill
Remote monitoring is being reshaped by the same logic.
CMS created new remote physiologic and remote therapeutic monitoring codes for
fewer than sixteen days of data transmission in a thirty-day period, closing a
gap that previously left short-duration episodes such as post-discharge
recovery unbillable. CMS also finalised the use of hospital outpatient payment
data to set rates for some remote monitoring services, an approach it says
promotes price transparency and more predictable rate-setting. The direction of
travel is toward reimbursing monitoring in the shorter, more clinically varied
episodes in which it is actually used.
Care moves home: hospital-at-home
The Consolidated Appropriations Act, 2026 extended the
Acute Hospital Care at Home waiver through 30 September 2030 and established an
interim study and report on the initiative [10]. CMS, through its data
contractor, notes that the programme has now been extended by Congress several
times since the pandemic emergency, and it has released research files covering
April 2023 through September 2025 [24]. A five-year horizon is long enough for
health systems to justify investment in the monitoring, logistics and
virtual-visit infrastructure that home-based acute care requires, which in turn
deepens demand for the telemedicine tools that sit inside it.
Artificial Intelligence: Real Deployment, Thin Evidence,
Cautious Regulators
Ambient documentation: modest, measurable, contested
The best current evidence on generative AI in clinical
workflow comes from a randomised trial published in NEJM AI, in which 238
outpatient physicians across 14 specialties were assigned to one of two ambient
scribe products or to usual care. The authors found a modest reduction in time
spent on documentation among users of one product and no significant change for
the other, and they observed possible improvements in burnout, task load and
work exhaustion for users of both, which they say need confirmation in larger
multicentre trials. They also note that occasional inaccuracies require ongoing
clinician vigilance. For telemedicine operators, whose clinicians conduct high
volumes of short encounters, the takeaway is that documentation AI is likely to
help with workload and retention before it delivers hard productivity gains.
Regulators are still defining the perimeter
Regulation is moving more slowly than deployment,
especially in behavioural health, where consumer-facing chatbots are
proliferating. The FDA's Digital Health Advisory Committee met on November 2025
specifically on generative AI-enabled digital mental health devices, and FDA's
own briefing notes that none of the AI-enabled devices it has authorised yet
involves generative AI for mental health conditions. That gap defines a
commercial boundary. Virtual mental health providers can use AI for scheduling,
matching, documentation and triage support today, but a product that claims to
diagnose or treat with generative AI would require a regulatory pathway that
does not yet exist in mature form.
Risks, Open Questions and What to Watch
The following assessment is analytical judgement rather
than reported fact. Three dates matter most. The first is December 2026, when
the DEA controlled-substance flexibilities expire unless a final rule or
another extension arrives, the recent submission of a final rule for OMB review
suggests that a decision is close, but its content and timing are uncertain.
The second December 2027, when the Medicare flexibilities and behavioural
in-person visit waivers lapse absent further legislation. The third is 2027
more broadly, when WHO is expected to put a new global digital health strategy
to the World Health Assembly and when Teladoc One will first be visible in
broad commercial use.
Beyond the calendar, four open questions deserve
attention. Whether ACCESS produces credible outcome evidence will determine
whether outcome-aligned payment spreads to commercial payers. Whether AI
documentation tools deliver more than modest workload relief will affect the
economics of high-volume virtual clinics. Whether cash-pay telehealth can be
sustained as insurance coverage expands is an open question that Teladoc's
BetterHelp results raise sharply, and it bears on every direct-to-consumer
model. And whether Hims & Hers can restore margin while scaling
internationally will indicate whether the consumer platform model is a durable
business or a growth phase. Provider capacity is the constraint that runs
through all of them, as Teladoc's comments on insurance demand exceeding
provider supply make plain.
Conclusion
Telemedicine has moved from a technology story to a
systems story. The video visit is now table stakes, and the market's direction
is being set by how long policymakers commit to reimbursing it, whether payers
will pay for outcomes instead of activity, whether AI can lift clinician
capacity without adding risk, and whether companies can build economic models
that survive the loss of cash-pay demand or temporary regulatory relief. The
evidence in 2026 points to a market that is consolidating around accountable,
integrated and infrastructure-like offerings, and to a policy environment that
has improved in clarity but not yet in permanence. Organisations that treat
telemedicine as a channel will find it commoditising, while those that treat it
as the delivery layer of a managed clinical relationship are better placed to
benefit from where payment and policy are moving.